Menu Search
Equities

Edding Genor Group Holdings Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
67N0:FRA

Edding Genor Group Holdings Ltd

Actions
  • Price (EUR)0.294
  • Today's Change0.018 / 6.52%
  • Shares traded1.33k
  • 1 Year change+41.35%
  • Beta1.2071
Data delayed at least 15 minutes, as of Feb 06 2026 07:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Edding Genor Group Holdings Ltd, formerly Genor Biopharma Holdings Ltd, is a company primarily engaged in developing and commercialising oncology and autoimmune drugs. The Company’s main business is engaged in the discovery, development and commercialization of biopharmaceutical products for human use. The Company’s product pipelines include Lerociclib (GB491), GB261, GB263T, Infliximab (GB242), Coprelotamab (GB221), GB223, Rituximab (GB241), Vancocin, Ceclor and other products, covering disease fields such as breast cancer, lung cancer, gastrointestinal tumors, and blood tumors. The Company mainly conducts its business in the domestic market.

  • Revenue in HKD (TTM)252.10m
  • Net income in HKD22.67m
  • Incorporated2017
  • Employees17.00
  • Location
    Edding Genor Group Holdings Ltd89 Nexus Way, Camana Bay,P.O. Box 31106SHANGHAI 201203ChinaCHN
  • Phone+86 2 161690700
  • Websitehttps://www.eddingpharm.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.